Literature DB >> 32147964

Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease.

Mariam Kayle1, Jhaqueline Valle2, Susan Paulukonis2, Jane L Holl3, Paula Tanabe1, Dustin D French4,5,6, Ravi Garg5, Robert I Liem7,8, Sherif M Badawy7,8, Marsha J Treadwell9.   

Abstract

PURPOSE: Sickle cell disease (SCD) is associated with high acute healthcare utilization. The purpose of this study was to examine whether Medicaid expansion in California increased Medicaid enrollment, increased hydroxyurea prescriptions filled, and decreased acute healthcare utilization in SCD.
METHODS: Individuals with SCD (≤65 years and enrolled in Medicaid for ≥6 total calendar months any year between 2011 and 2016) were identified in a multisource database maintained by the California Sickle Cell Data Collection Program. We describe trends and changes in Medicaid enrollment, hydroxyurea prescriptions filled, and emergency department (ED) visits and hospital admissions before (2011-2013) and after (2014-2016) Medicaid expansion in California.
RESULTS: The cohort included 3635 individuals. Enrollment was highest in 2014 and lowest in 2016 with a 2.8% annual decease postexpansion. Although <20% of the cohort had a hydroxyurea prescription filled, the percentage increased by 5.2% annually after 2014. The ED visit rate was highest in 2014 and decreased slightly in 2016, decreasing by 1.1% annually postexpansion. Hospital admission rates were similar during the pre- and postexpansion periods. Young adults and adults had higher ED and hospital admission rates than children and adolescents.
CONCLUSIONS: Medicaid expansion does not appear to have improved enrollment or acute healthcare utilization among individuals with SCD in California. Future studies should explore whether individuals with SCD transitioned to other insurance plans or became uninsured postexpansion, the underlying reasons for low hydroxyurea utilization, and the lack of effect on hospital admissions despite a modest effect on ED visits.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  Medicaid expansion; health disparity; healthcare utilization; hydroxyurea; sickle cell disease

Mesh:

Substances:

Year:  2020        PMID: 32147964      PMCID: PMC7096276          DOI: 10.1002/pbc.28152

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  28 in total

1.  Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.

Authors:  David C Brousseau; Troy Richardson; Matt Hall; Angela M Ellison; Samir S Shah; Jean L Raphael; David G Bundy; Staci Arnold
Journal:  Pediatrics       Date:  2019-07       Impact factor: 7.124

2.  Emergency department utilization by Californians with sickle cell disease, 2005-2014.

Authors:  Susan T Paulukonis; Lisa B Feuchtbaum; Thomas D Coates; Lynne D Neumayr; Marsha J Treadwell; Elliott P Vichinsky; Mary M Hulihan
Journal:  Pediatr Blood Cancer       Date:  2016-12-21       Impact factor: 3.167

3.  Examination of the Patient and Hospitalization Characteristics of 30-Day SCD Readmissions.

Authors:  C Patrick Carroll; Carlton Haywood; Sophie M Lanzkron
Journal:  South Med J       Date:  2016-09       Impact factor: 0.954

4.  Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease.

Authors:  Carlton Haywood; Mary Catherine Beach; Shawn Bediako; C Patrick Carroll; Lakshmi Lattimer; Dasheema Jarrett; Sophie Lanzkron
Journal:  Am J Hematol       Date:  2011-01       Impact factor: 10.047

5.  Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort.

Authors:  Maa-Ohui Quarmyne; Wei Dong; Rodney Theodore; Sonia Anand; Vaughn Barry; Olufolake Adisa; Iris D Buchanan; James Bost; Robert C Brown; Clinton H Joiner; Peter A Lane
Journal:  Am J Hematol       Date:  2016-11-18       Impact factor: 10.047

6.  Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.

Authors:  Sean D Candrilli; Sarah H O'Brien; Russell E Ware; Milap C Nahata; Eric E Seiber; Rajesh Balkrishnan
Journal:  Am J Hematol       Date:  2011-02-15       Impact factor: 10.047

Review 7.  Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.

Authors:  John J Strouse; Sophie Lanzkron; Mary Catherine Beach; Carlton Haywood; Haeseong Park; Catherine Witkop; Renee F Wilson; Eric B Bass; Jodi B Segal
Journal:  Pediatrics       Date:  2008-12       Impact factor: 7.124

Review 8.  Differences in the clinical and genotypic presentation of sickle cell disease around the world.

Authors:  Santosh L Saraf; Robert E Molokie; Mehdi Nouraie; Craig A Sable; Lori Luchtman-Jones; Gregory J Ensing; Andrew D Campbell; Sohail R Rana; Xiao M Niu; Roberto F Machado; Mark T Gladwin; Victor R Gordeuk
Journal:  Paediatr Respir Rev       Date:  2013-11-15       Impact factor: 2.726

9.  The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization.

Authors:  C Patrick Carroll; Carlton Haywood; Peter Fagan; Sophie Lanzkron
Journal:  Am J Hematol       Date:  2009-10       Impact factor: 10.047

10.  US Emergency Department Visits and Hospital Discharges Among Uninsured Patients Before and After Implementation of the Affordable Care Act.

Authors:  Adam J Singer; Henry C Thode; Jesse M Pines
Journal:  JAMA Netw Open       Date:  2019-04-05
View more
  2 in total

1.  The Montreal cognitive assessment as a cognitive screening tool in sickle cell disease: Associations with clinically significant cognitive domains.

Authors:  Macy L Early; Elizabeth Linton; Allison Bosch; Timothy Campbell; Felicia Hill-Briggs; Lydia H Pecker; Eboni I Lance; Sophie Lanzkron
Journal:  Br J Haematol       Date:  2022-04-06       Impact factor: 8.615

Review 2.  Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research.

Authors:  Scott D Grosse; Nancy S Green; Sarah L Reeves
Journal:  Pediatr Blood Cancer       Date:  2020-09-17       Impact factor: 3.838

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.